✦ LIBER ✦

Inhibition by CV-3988 of the binding of [3H]-platelet activating factor (PAF) to the platelet

✍ Scribed by Zen-Ichi Terashita; Yoshimi Imura; Kohei Nishikawa

Book ID: 115778569
Publisher: Elsevier Science
Year: 1985
Tongue: English
Weight: 423 KB
Volume: 34
Category: Article
ISSN: 0006-2952
DOI: 10.1016/0006-2952(85)90689-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

CV-3988 - A specific antagonist of plate

CV-3988 - A specific antagonist of platelet activating factor (PAF)

✍ Zen-ichi Terashita; Susumu Tsushima; Yoshio Yoshioka; Hiroaki Nomura; Yoshiyuki 📂 Article 📅 1983 🏛 Elsevier Science 🌐 English ⚖ 418 KB

Effects of cv-3988, an antagonist of pla

Effects of cv-3988, an antagonist of platelet-activating factor (paf), on washed rabbit platelets

✍ Charles P. Cox 📂 Article 📅 1986 🏛 Elsevier Science 🌐 English ⚖ 685 KB

Triazolobenzodiazepines competitively in

Triazolobenzodiazepines competitively inhibit the binding of platelet activating factor (PAF) to human platelets

✍ Carolyn M. Chesney; D. David Pifer; Lauren M. Cagen 📂 Article 📅 1987 🏛 Elsevier Science 🌐 English ⚖ 317 KB

Possible role of platelet activating fac

Possible role of platelet activating factor (PAF) in disseminated intravascular coagulation (DIC), evidenced by use of a PAF antagonist, CV-3988

✍ Yoshimi Imura; Zen-ichi Terashita; Kohei Nishikawa 📂 Article 📅 1986 🏛 Elsevier Science 🌐 English ⚖ 401 KB

Inhibition of binding of the platelet-ac

Inhibition of binding of the platelet-activating factor AGEPC to platelets by the AGEPC analog rac-3-(N-n-octadecylcarbamoyloxy)-2-methoxypropyl 2-thiazolioethyl phosphate (CV-3988)

✍ Frank H. Valone 📂 Article 📅 1985 🏛 Elsevier Science 🌐 English ⚖ 399 KB

The specificity of the binding of platel

The specificity of the binding of platelet activating factor (PAF) to anti-PAF antibodies

✍ Mary A. Smal; Brian A. Baldo; David G. Harle 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 510 KB

## Abstract Quantitative hapten inhibition experiments employing sheep anti‐PAF antibodies and selected PAF analogues were undertaken with the aim of defining the antigenic determinant structures complementary to the antibody combining sites. The most important fine structural features for inhibiti